Royalty Pharma RPRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.38B+5.1% | $2.26B-3.9% | $2.35B+5.2% | $2.24B-2.3% | ||
| $452M+22,500% | $2M-96.2% | $52M-70.6% | $177.11M-11.5% | ||
| $573.48M+142% | $236.67M-5.2% | $249.75M+9.9% | $227.3M+24.3% | ||
| $818.67M-15.7% | $971.13M+10.5% | $879.23M-54.4% | $1.93B+125% | ||
| $1.56B+20.7% | $1.29B-13.4% | $1.49B— | —— | ||
| 65.6%+8.5pp | 57.1%-6.3pp | 63.4%— | —— | ||
| $307.66M+36.4% | $225.51M+20.5% | $187.19M-0.4% | $187.96M+13.1% | ||
| -$234.33M— | —— | $207.94M+370% | -$77M+59.4% | ||
| $1.33B-0.4% | $1.33B-21.7% | $1.7B— | —— | ||
| $0— | $0— | $0— | $0— | ||
| $771.95M-10.1% | $858.98M-24.3% | $1.13B— | —— | ||
| 32.5%-5.5pp | 37.9%-10.2pp | 48.2%— | —— | ||
| $1.79-6.8% | $1.92-23.8% | $2.52— | —— | ||
| $1.56B+20.7% | $1.29B-13.4% | $1.49B— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
